Drug intelligence / Profile preview

ODM-216

Development stage: Phase 2
Lead developer: Orion
Modality: Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
Administration: Intravenous, Subcutaneous

Overview

ODM-216 is a bispecific antibody developed by Orion for the treatment of cancer. It is a biologic (large molecule) originating from Orion's internal research and is currently in late research or preclinical development. The drug is designed as an immuno-oncology agent, with its primary indication being neoplasms (cancer). Clinical phase I trials are planned to start within the next 12 to 24 months in Finland. As a bispecific antibody, ODM-216 likely targets two different antigens or epitopes simultaneously to enhance anti-tumor immune responses[1][2][8].

Other names: ODM-216ODM216ODM 216

Targets

PVRIG (Poliovirus receptor related immunoglobulin domain containing protein)CD274 (Programmed cell death protein 1 ligand 1)

Beyond the preview

Go deeper on ODM-216.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ODM-216.